Aristada
E597293
Aristada is a long-acting injectable antipsychotic medication (aripiprazole lauroxil) used primarily to treat schizophrenia in adults.
Observed surface forms (1)
| Surface form | Occurrences |
|---|---|
| Aristada Initio | 1 |
Statements (49)
| Predicate | Object |
|---|---|
| instanceOf |
atypical antipsychotic
ⓘ
brand name drug ⓘ long-acting injectable antipsychotic medication ⓘ |
| approvalYearUS | 2015 ⓘ |
| approvedBy | U.S. Food and Drug Administration NERFINISHED ⓘ |
| ATCCode | N05AX12 (aripiprazole) ⓘ |
| availableStrength |
1064 mg
ⓘ
441 mg ⓘ 662 mg ⓘ 882 mg ⓘ |
| commonAdverseEffect |
akathisia
ⓘ
anxiety ⓘ injection site pain ⓘ insomnia ⓘ weight gain ⓘ |
| countryApprovedIn | United States NERFINISHED ⓘ |
| dosingInterval |
every 4 weeks
ⓘ
every 6 weeks ⓘ every 8 weeks ⓘ |
| formulation | extended-release injectable suspension ⓘ |
| hasActiveIngredient | aripiprazole lauroxil NERFINISHED ⓘ |
| hasBoxedWarning | increased mortality in elderly patients with dementia-related psychosis ⓘ |
| hasLoadingDoseOption | true ⓘ |
| indicatedFor | schizophrenia in adults ⓘ |
| injectionSite |
deltoid muscle (for some doses)
ⓘ
gluteal muscle ⓘ |
| isLongActing | true ⓘ |
| isProdrugOf | aripiprazole NERFINISHED ⓘ |
| legalStatusUS | prescription only ⓘ |
| loadingRegimenBrand | Aristada Initio NERFINISHED ⓘ |
| marketingAuthorizationHolder | Alkermes plc NERFINISHED ⓘ |
| metabolism |
CYP2D6
ⓘ
CYP3A4 ⓘ |
| notApprovedFor | treatment of dementia-related psychosis ⓘ |
| oralOverlapDrug | oral aripiprazole ⓘ |
| oralOverlapDuration | 21 days (for most initiation regimens) ⓘ |
| pharmacologicClass |
dopamine D2 receptor partial agonist
ⓘ
serotonin 5-HT1A receptor partial agonist ⓘ serotonin 5-HT2A receptor antagonist ⓘ |
| pregnancyCategoryUS | not assigned (use only if benefit justifies risk) ⓘ |
| requiresOralOverlap | true ⓘ |
| routeOfAdministration | intramuscular injection ⓘ |
| seriousAdverseEffect |
leukopenia
ⓘ
neuroleptic malignant syndrome ⓘ orthostatic hypotension ⓘ seizures ⓘ tardive dyskinesia ⓘ |
| targetPopulation | adults with schizophrenia ⓘ |
| therapeuticArea | psychiatry ⓘ |
Referenced by (2)
Full triples — surface form annotated when it differs from this entity's canonical label.